Physician profile
Robin B Severance
NPI 1417942848
$8,521.27
in general payments reported to CMS, 2019-2025
26 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,028 · 2022: $1,408 · 2023: $2,002 · 2024: $2,178 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,936 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,935.87 |
| Education | $148.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,181.71 | 2021-2025 | |
| Amgen INC. | $1,911.76 | 2021-2025 | Enbrel, Evenity, Tavneos |
| Janssen Biotech, INC. | $824.82 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| Ucb, INC. | $622.87 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $352.44 | 2021-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $320.01 | 2021-2024 | |
| Pfizer INC. | $308.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $300.09 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $279.83 | 2024-2025 | Orencia |
| Fresenius Kabi USA, LLC | $218.76 | 2023-2025 | |
| Horizon Therapeutics Plc | $198.79 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.39 | 2022-2025 | Cyltezo, Spevigo |
| Ani Pharmaceuticals, INC. | $139.62 | 2024-2025 | Purified Cortrophin Gel |
| Organon LLC | $123.02 | 2023-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $99.90 | 2023-2025 | Benlysta, Nucala |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $81.87 | 2021-2025 | Tymlos |
| Sobi, INC | $80.37 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $74.37 | 2022 | |
| Genentech USA, INC. | $52.22 | 2023-2025 | Actemra |
| Stryker Corporation | $39.70 | 2024 | Augment Injectable |
| Alexion Pharmaceuticals, INC. | $38.61 | 2024-2025 | Strensiq |
| Genzyme Corporation | $35.03 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $31.93 | 2023 | Lupkynis |
| Depuy Synthes Sales INC. | $23.24 | 2025 | Monovisc, Orthovisc |
| Hikma Pharmaceuticals USA | $23.03 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.22 | 2024 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Severance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.